Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways

Laura Mazzera, PhD, Manuela Abeltino, PhD, Antonio Bonati, MD, Paolo Lunghi, PhD

Blood (2017) 130 (Supplement 1): 2520.

https://doi.org/10.1182/blood.V130.Suppl_1.2520.2520

Published: 2017

Journal Articles

Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL

Laura Mazzera, Guerino Lombardi, Manuela Abeltino, Micaela Ricca, Gaetano Donofrio, Nicola Giuliani, Anna Maria Cantoni, Attilio Corradi, Antonio Bonati, Paolo Lunghi

Blood (2013) 122 (15): 2641–2653.

https://doi.org/10.1182/blood-2013-02-482356

Published: 2013

Includes: Supplemental data

Journal Articles

Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model

Paolo Lunghi, PhD, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Manuela Abeltino, Davide Arienti, Anna Maria Cantoni, Attilio Corradi, Antonio Bonati, MD

Blood (2011) 118 (21): 1846.

https://doi.org/10.1182/blood.V118.21.1846.1846

Published: 2011

Journal Articles

Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma

Paolo Lunghi, PhD, Laura Mazzera, Manuela Abeltino, Nicola Giuliani, Antonio Bonati, MD

Blood (2010) 116 (21): 4059.

https://doi.org/10.1182/blood.V116.21.4059.4059

Published: 2010

Journal Articles

Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Mieloma Cells Sensitive and Resistant to Bortezomib.

Paolo Lunghi, Laura Mazzera, Antonio Costanzo, Nicola Giuliani, Vittorio Rizzoli, Massimo Levrero, Antonio Bonati

Blood (2009) 114 (22): 1837.

https://doi.org/10.1182/blood.V114.22.1837.1837

Published: 2009

Journal Articles

Arsenic Trioxide (ATO) Interacts Synergistically with MEK Inhibitors to Induce Apoptosis in STI571-Resistant Bcr-Abl Mutants.

Paolo Lunghi, Laura Mazzera, Attilio Corradi, Anna Maria Cantoni, Stefano Jottini, Guerino Lombardi, Micaela Ricca, Davide Arienti, Vittorio Rizzoli, Michael WN Deininger, MD, Antonio Bonati, MD

Blood (2009) 114 (22): 2177.

https://doi.org/10.1182/blood.V114.22.2177.2177

Published: 2009

Journal Articles

Phorbol ester–induced PKCϵ down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation

Giuliana Gobbi, Prisco Mirandola, Cecilia Carubbi, Cristina Micheloni, Chiara Malinverno, Paolo Lunghi, Antonio Bonati, Marco Vitale

Blood (2009) 113 (13): 3080–3087.

https://doi.org/10.1182/blood-2008-03-143784

Published: 2009

Includes: Supplemental data

Journal Articles

Hypoxia and Hypoxia Inducible Factor (HIF)-1α in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment.

Simona Colla, Paola Storti, Gaetano Donofrio, Mirca Lazzaretti, Sabrina Bonomini, Paolo Lunghi, Monica Crugnola, Marina Bolzoni, Luisa Galla, Luigi Ippolito, Eugenia Martella, Gabriella Sammarelli, Luisa Craviotto, Cecilia Caramatti, Marcellina Mangoni, Antonio Bonati, Vittorio Rizzoli, Nicola Giuliani

Blood (2008) 112 (11): 1687.

https://doi.org/10.1182/blood.V112.11.1687.1687

Published: 2008

Journal Articles

Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model.

Paolo Lunghi, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Attilio Corradi, Anna Maria Cantoni, Nicola Giuliani, Luigi Salvatore, Roberta Riccioni, Antonio Costanzo, Ugo Testa, Massimo Levrero, Vittorio Rizzoli, Antonio Bonati

Blood (2008) 112 (11): 1712.

https://doi.org/10.1182/blood.V112.11.1712.1712

Published: 2008

Journal Articles

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways

Paolo Lunghi, Nicola Giuliani, Laura Mazzera, Guerino Lombardi, Micaela Ricca, Attilio Corradi, Anna Maria Cantoni, Luigi Salvatore, Roberta Riccioni, Antonio Costanzo, Ugo Testa, Massimo Levrero, Vittorio Rizzoli, Antonio Bonati

Blood (2008) 112 (6): 2450–2462.

https://doi.org/10.1182/blood-2007-10-114348

Published: 2008

Includes: Supplemental data

Journal Articles

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α) activity: involvement in myeloma-induced angiogenesis

Blood (2007) 110 (13): 4464–4475.

https://doi.org/10.1182/blood-2007-02-074617

Published: 2007

Journal Articles

Targeting MEK/MAPK Signal Transduction Module Potentiates Arsenic Trioxide (ATO)-Induced Apoptosis in Multiple Myeloma Cells through Multiple Signaling Pathways.

Paolo Lunghi, Nicola Giuliani, Laura Mazzera, Francesca Morandi, Luigi Salvatore, Marcellina Mangoni, Vittorio Rizzoli, Antonio Bonati

Blood (2007) 110 (11): 1517.

https://doi.org/10.1182/blood.V110.11.1517.1517

Published: 2007

Journal Articles

MEK1 Blockade Sensitizes Multiple Myeloma Tumor Cells to Arsenic Trioxide (ATO)-Induced Apoptosis: A Functional and Molecular Study.

Paolo Lunghi, PhD, Nicola Giuliani, MD, Laura Mazzera, PhD, Francesca Morandi, PhD, Vittorio Rizzoli, MD, Antonio Bonati, MD

Blood (2006) 108 (11): 1372.

https://doi.org/10.1182/blood.V108.11.1372.1372

Published: 2006

Journal Articles

Mdm2 Inhibitor Nutlin-3 Enhances the Cytotoxic Synergism Induced by the Combination of MEK1 Inhibitor and Arsenic Trioxide (ATO) in AML Cells.

Paolo Lunghi, PhD, Laura Mazzera, PhD, Vittorio Rizzoli, MD, Antonio Bonati, MD

Blood (2006) 108 (11): 1364.

https://doi.org/10.1182/blood.V108.11.1364.1364

Published: 2006

Journal Articles

p29ING4 Regulates the Production of Pro-Angiogenic Molecules by Human Myeloma Cells in Normoxic and Hypoxic Conditions Being Involved in Myeloma-Induced Angiogenesis.

Sara Tagliaferri, Francesca Morandi, Paolo Lunghi, Simona Colla, Mirca Lazzaretti, Cristina Mancini, Daniela Drandi, Marco Ladetto, Antonio Bonati, Vittorio Rizzoli, Nicola Giuliani

Blood (2006) 108 (11): 515.

https://doi.org/10.1182/blood.V108.11.515.515

Published: 2006

Journal Articles

MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide–induced apoptosis

Paolo Lunghi, Antonio Costanzo, Luigi Salvatore, Nelida Noguera, Laura Mazzera, Antonio Tabilio, Francesco Lo-Coco, Massimo Levrero, Antonio Bonati

Blood (2006) 107 (11): 4549–4553.

https://doi.org/10.1182/blood-2005-07-2829

Published: 2006

Journal Articles

Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts.

Paolo Lunghi, PhD, Antonio Costanzo, MD, Luigi Salvatore, PhD, Nelida Noguera, PhD, Antonio Tabilio, MD, Francesco Lo Coco, MD, Massimo Levrero, MD, Antonio Bonati, MD

Blood (2005) 106 (11): 613.

https://doi.org/10.1182/blood.V106.11.613.613

Published: 2005

Journal Articles

MEK1 Inhibition and Arsenic Trioxide Synergize To Induce Apoptosis of Acute Myeloid Leukemia Blasts.

Paolo Lunghi, Luigi Salvatore, Nelida Noguera, Pier Giuseppe, Pelicci, Francesco Lo, Coco, Antonio Bonati

Blood (2004) 104 (11): 3397.

https://doi.org/10.1182/blood.V104.11.3397.3397

Published: 2004

Journal Articles

Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells

Paolo Lunghi, Antonio Costanzo, Massimo Levrero, Antonio Bonati

Blood (2004) 104 (2): 519–525.

https://doi.org/10.1182/blood-2003-08-2743

Published: 2004

Journal Articles

Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication

Loretta Gammaitoni, Katja C. Weisel, Monica Gunetti, Kai-Da Wu, Stefania Bruno, Silvana Pinelli, Antonio Bonati, Massimo Aglietta, Malcolm A. S. Moore, Wanda Piacibello

Blood (2004) 103 (12): 4440–4448.

https://doi.org/10.1182/blood-2003-09-3079

Published: 2004

NARROW

The Pharmacological Blockade of Phosphodiesterase IV Potentiates the Anti-Tumor Effects of Arsenic Trioxide (ATO) in Acute Myelogenous Leukemia Cells through Multiple Signaling Pathways

Aurora and IKK kinases cooperatively interact to protect multiple myeloma cells from Apo2L/TRAIL

Pan-Aurora Kinases and TRAIL Combination Therapy Has Potent Antitumor Activity In Vivo Against Drug-Resistant Human Multiple Myeloma Xenograft Model

Blockade of Aurora Kinase Activity Enhances Apo2L/TRAIL Sensitivity In Multiple Myeloma

Pan-Aurora Kinase Inhibitor Mk-0457 Synergistically Potentiates Apo2L/Trail Cytotoxicity in Multiple Mieloma Cells Sensitive and Resistant to Bortezomib.

Arsenic Trioxide (ATO) Interacts Synergistically with MEK Inhibitors to Induce Apoptosis in STI571-Resistant Bcr-Abl Mutants.

Phorbol ester–induced PKCϵ down-modulation sensitizes AML cells to TRAIL-induced apoptosis and cell differentiation

Hypoxia and Hypoxia Inducible Factor (HIF)-1α in Multiple Myeloma: Effect on the Pro-Angiogenic Signature of Myeloma Cells and the Bone Marrow Microenvironment.

Combined Treatment with the Mek Inhibitor PD0325901 and Arsenic Trioxide Has Potent Antitumor Activity in Vivo against Human Multiple Myeloma Xenograft Model.

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways

The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 α (HIF-1α) activity: involvement in myeloma-induced angiogenesis

Targeting MEK/MAPK Signal Transduction Module Potentiates Arsenic Trioxide (ATO)-Induced Apoptosis in Multiple Myeloma Cells through Multiple Signaling Pathways.

MEK1 Blockade Sensitizes Multiple Myeloma Tumor Cells to Arsenic Trioxide (ATO)-Induced Apoptosis: A Functional and Molecular Study.

Mdm2 Inhibitor Nutlin-3 Enhances the Cytotoxic Synergism Induced by the Combination of MEK1 Inhibitor and Arsenic Trioxide (ATO) in AML Cells.

p29ING4 Regulates the Production of Pro-Angiogenic Molecules by Human Myeloma Cells in Normoxic and Hypoxic Conditions Being Involved in Myeloma-Induced Angiogenesis.

MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide–induced apoptosis

Arsenic Trioxide (ATO) and MEK1 Inhibitor Activate Apoptotic p73 Pathway in Primary Acute Myelogenous Leukemia Blasts.

MEK1 Inhibition and Arsenic Trioxide Synergize To Induce Apoptosis of Acute Myeloid Leukemia Blasts.

Treatment with arsenic trioxide (ATO) and MEK1 inhibitor activates the p73-p53AIP1 apoptotic pathway in leukemia cells

Elevated telomerase activity and minimal telomere loss in cord blood long-term cultures with extensive stem cell replication

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only